Biocon beats recession
Industry experts
forecast a business environment recovery only in 2010. But
Biocon’s first quarter results indicate a quicker upsurge.
Withstanding the economic downturn, Biocon, the Indian biotechnology
leader, has performed strongly in the first quarter of the current
financial year. The 20th leading global biotech company surprised the
market with an unexpected upsurge of 83 percent. This year, the revenue
shot to a high of Rs 505 crore in Q1 from Rs 277 crore recorded last
year during the same period. Fiscal year 2009 poses one of the most
challenging years for Biocon, where foreign currency volatility has
made it difficult to manage a sharp depreciating rupee, resulting in a
large Market-to-Market (MTM) losses. But considering the last fiscal as
a year of learning and reckoning, Biocon is back on the growth track
ready to grow aggressively in 2009-10.
Revenue analysis
Biocon’s Q1 consolidated revenues stood at Rs 505 crore
including the business from its German subsidiary, AxiCorp. It has been
a year since the German company came on board as Biocon’s
subsidiary company, and during this short time, the company has
delivered a significant value of Rs 190 crore of the total revenue,
which did not figure in last year’s financials.
AxiCorp is a distribution business with a radically different operating
parameters; therefore, it is a top line contributor with minimal
addition to bottom line. It will add to bottom line when
Biocon’s insulin gets marketing authorization in Europe. The
company expects this to take place over the next 18-24 months.
Registration process has already started in Europe where it is
conducting clinical trials, both phase I and phase III.
In terms of its EBITDA performance, Biocon has grown robustly. This has
increased substantially over the last one year to Rs 111 crore, and to
exclude AxiCorp, it has actually delivered at over 40 percent profit
after tax (PAT). It had to take a huge hit in the first quarter of last
year, when Biocon hardly was able to declare a PAT of Rs 15
crore, on account of MTM losses. In this year’s first
quarter, PAT increased to Rs 58 crore, thus registering a
huge jump of 283 percent. During 2008-09, Biocon experienced sharp
losses and decline in profit. However, the sudden upswing in business
revenue has boosted the confidence of the company and its
shareholders.
The market share of the company also increased during the period. Some
of its key operational areas, like oncology and diabetic
product segment have seen an upsurge. The company is also expanding its
network coverage. Last year, it took a giant step towards
consolidating its presence in Gulf Cooperation Council (GCC) markets.
Its joint venture in Abu Dhabi, NeoBiocon, launched Abraxane
in the UAE market for breast cancer treatment.
Commenting on the results, Dr Kiran Mazumdar Shaw, CMD, Biocon says,
“Biocon’s Q1’10 performance has delivered
robust growth across all segments. This, we believe, is a trend that
holds good prospects for the year ahead. We are making excellent
progress on the research front with several programs approaching a
licensing potential. We envisage that this will deliver excellent
returns on our R&D investments.”
Riding high on services
In the first quarter performance, the company’s services
sector, namely Syngene and Clinigene have shown strong performance.
Syngene contributed significantly to its first quarter’s
services’ numbers. Refering to the services’
business performance Dr Shaw says, “Syngene had a
particularly strong quarter demonstrating good returns on the
investments made over the last two years. We expect our pre-clinical
and biological services to expand our customer base and increase
business revenues for future quarters.” Syngene business grew
from Rs 38 crore last fiscal to
Rs 58 crore in Q1 this fiscal. Similarly, Clinigene grew from Rs 6
crore to Rs 9 crore, and collectively registered a boisterous growth.
Although PAT is a little muted, mainly due to the interest and
depreciation components which Syngene had to carry, the company expects
these investments to generate good growth and good return for Biocon.
Large part of these investments were made to create a dedicated
research facility for BMS (Bristol Myers Squib). BMS contract services
have contributed almost close to 30 percent of
Syngene’s numbers.
The company’s healthcare business too have continued to build
a strong portfolio of products for diabetology, oncology, nephrology,
and cardiovascular diseases. The diabetology division has grown to an
impressive 12th rank in ORG rankings from a starting position of 40 in
2005. Apart from bolstering its existing portfolio,
it also had an impressive launch of Insugen 100 and an insulin analog,
Basalog, which is a bio-generic insulin Glargine. Biocon’s
cardiology division has also been steadily building its legacy
portfolio of statins and anti-hypertensives with an impressive range of
other new launches. The oncotherapeutics division has continued to grow
with BioMAb EGFR – a novel monoclonal antibody for the
treatment of head and neck cancer, and has been further bolstered with
the addition of Abraxane, (in-licensed from Abraxis Biosciences, theUS)
and its supportive care portfolio of products like Granulocyte
Colony-Stimulating Factor (GCSF) and Erythropoietin (EPO).
The company’s proprietary product BioMAb-EGFR is currently
being tried as first line combination therapy in late phase trials in
NSCLC (in combination with carboplatin and docetaxel) and Glioma (in
combination with temozolomide and radiation therapy). Recruitment for
the NSCLC trial is continuing, while accrual for the Glioma trial has
reached its target accrual. Other multiple clinical trials led by the
global consortium of partners for the development of BioMAb-EGFR are
either planned, on-going or completed. These include trials in head and
neck cancers, cervical cancer, esophageal cancer, diffuse intrinsic
pontine glioma, pediatric glioma, pancreatic cancer and colorectal
cancer.
Focus on biogenerics
Biocon is aggressively focussing on novel biologics and biogenerics.
And like many other big biopharma players, Biocon too is betting on the
novelty of upcoming US Biosimilar Bill. Acccording to Dr
Shaw, the Bill will open up a very lucrative opportunity for
Biocon. She states, “Today, we have a very rich pipeline of
biosimilars or biogeneric antibodies. And these are antibodies that are
going to come off patent in the next few years. So it will give us
continuous market opportunity in the short, medium and long term, which
makes this whole opportunity very exciting.” She continued,
“Biocon is in a very unique position to take advantage of
this whole thing. We have already started that process with our
insulins and glargine. These products will enter that regulatory
process quite soon. Our insulin is already there, and our
glargine will soon follow. We’ll have some special advantages
because we have the infrastructure in place to quickly develop
biogenerics for this kind of very challenging and highly regulated
markets.”
Strengthening its position in biogenerics, Biocon recently signed a
pact with Mylan, the global generics pharma major. Biocon executed a
definitive agreement with Mylan for an exclusive collaboration on the
development, manufacturing, supply, commercialization of multiple and
high value generic biologic compounds for the global marketplace. The
deal between the two giants have brought together highly complementary
capabilities that will significantly advance their efforts to secure a
leading position in the emerging generic biologics industry.
![](/IMG/041/45041/kiran.gif)
In terms of novel biologics, the company is also making a good
progress. For instance, its oral insulin or IN-105 program is in phase
III clinical development, and patient enrollment is showing a
steady progress. The CD6 or the T1h program, which is making
a good progress is expected to commence phase III trials in psoriasis
soon.
In terms of its R&D spend, the company is likely to
continue its investment. Apart for the ones that Biocon is developing
in collaboration with Mylan, especially in the insulin segment, and
novel biologics and biogenerics, the former has also entered a
potential licensing and partnering phase.
The sequel of developments and the first quarter results clearly show
that the company has managed to recover from the MTM losses that it
encountered last year. And on account of the very prudent and cautious
approach, Biocon has taken to foreign exchange hedging.
Despite adverse economic climate, Biocon, fueled by a string of
pipeline product, remains resilent, poised and confident for
a heady growth, both in terms of revenue and profitability.
Jahanara Parveen